- Home
- MHN vs WGSWW Comparison
MHN vs WGSWW Comparison
Compare MHN & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHN
- WGSWW
- Stock Information
- Founded
- MHN 1997
- WGSWW 2017
- Country
- MHN United States
- WGSWW United States
- Employees
- MHN N/A
- WGSWW 1000
- Industry
- MHN Investment Bankers/Brokers/Service
- WGSWW Retail: Computer Software & Peripheral Equipment
- Sector
- MHN Finance
- WGSWW Technology
- Exchange
- MHN Nasdaq
- WGSWW Nasdaq
- Market Cap
- MHN 293.6M
- WGSWW N/A
- IPO Year
- MHN N/A
- WGSWW N/A
- Fundamental
- Price
- MHN $9.66
- WGSWW $0.11
- Analyst Decision
- MHN
- WGSWW
- Analyst Count
- MHN 0
- WGSWW 0
- Target Price
- MHN N/A
- WGSWW N/A
- AVG Volume (30 Days)
- MHN 59.2K
- WGSWW 36.6K
- Earning Date
- MHN 01-01-0001
- WGSWW 02-18-2025
- Dividend Yield
- MHN 4.17%
- WGSWW N/A
- EPS Growth
- MHN N/A
- WGSWW N/A
- EPS
- MHN N/A
- WGSWW N/A
- Revenue
- MHN N/A
- WGSWW $305,450,000.00
- Revenue This Year
- MHN N/A
- WGSWW N/A
- Revenue Next Year
- MHN N/A
- WGSWW N/A
- P/E Ratio
- MHN N/A
- WGSWW N/A
- Revenue Growth
- MHN N/A
- WGSWW 50.79
- 52 Week Low
- MHN $8.69
- WGSWW $0.17
- 52 Week High
- MHN $10.81
- WGSWW $0.21
- Technical
- Relative Strength Index (RSI)
- MHN 53.01
- WGSWW N/A
- Support Level
- MHN $9.52
- WGSWW N/A
- Resistance Level
- MHN $9.71
- WGSWW N/A
- Average True Range (ATR)
- MHN 0.06
- WGSWW 0.00
- MACD
- MHN 0.01
- WGSWW 0.00
- Stochastic Oscillator
- MHN 70.00
- WGSWW 0.00
About MHN Blackrock MuniHoldings New York Quality Fund Inc.
BLACKROCK MUNIHOLDINGS NEW YORK QUALITY FUND, INC. is a closed-ended management investment company. The fund's investment objective is to provide shareholders with current income exempt from federal income tax and New York State and New York City personal income taxes.
About WGSWW GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.